A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

NCT02702388 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

241

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Lenvatinib
DRUG: Lenvatinib matching placebo

Sponsor

Eisai Inc.

Collaborators

[object Object]